Healthcare

**Tenax Therapeutics Reports Q4 2025 Results**

Legend Biotech (NASDAQ: LEGN) reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting continued…

Editas Medicine reports Q4 loss of $0.06/share, narrower than the $0.21 consensus estimate.

Financial Performance and Liquidity Revenues for the fourth quarter of 2025 reached $30.3 million, an increase from $21.2 million in…

Biopharmaceutical company CorMedix Inc. (NASDAQ: CRMD) reported a sharp increase in revenues for the fourth quarter of fiscal 2025, primarily…

Biopharmaceutical company Liquidia Corporation (NASDAQ: LQDA) reported a profit for the fourth quarter of fiscal 2025, compared to a loss…

EyePoint, Inc. (NASDAQ: EYPT), which is engaged in the development of therapeutics for retinal diseases, on Wednesday announced financial results…

Optical retail company National Vision Holdings, Inc. (NASDAQ: EYE) on Wednesday announced financial results for the fourth quarter of FY25,…

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a biopharmaceutical company engaged in the discovery and development of cancer drugs, reported a narrower…

Ticker: CYRX | Exchange: NASDAQ | Report Date: March 3, 2026, after market close Cryoport, the specialized cold chain logistics…